| Properties | Information |
|---|---|
| PhytoCAT-ID | PhytoCAT-1898 |
| Phytochemical name or plant extracts | Apomorphine |
| PMID | 28465234 |
| Literature evidence | Our study has demonstrated that APO targets human MMP-9 in a DR-independent fashion in MCF-7 cells, suggesting that APO is a potential anticancer agent that can suppress the metastatic progression of cancer cells. |
| IUPAC name | (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol |
| Phytochemicals’ class or type of plant extracts | Alkaloid |
| Source of phytochemicals or plant Extracts | NA |
| Geographical availability | NA |
| Plant parts | NA |
| Other cancers | Breast cancer |
| Target gene or protein | NA |
| Gene or Protein evidence | NA |
| Target pathways | we have found that apomorphine (APO), a non-selective DRD1/DRD2 agonist, inhibited TNF-α-induced MMP-9 expression and cell invasion via DR-independent pathways in MCF-7 human breast cancer cells. |
| IC50 | NA |
| Potency | Our study has demonstrated that APO targets human MMP-9 in a DR-independent fashion in MCF-7 cells, suggesting that APO is a potential anticancer agent that can suppress the metastatic progression of cancer cells. |
| Cell line/ mice model | MCF-7 |
| Additional information | Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders. Apomorphine was granted FDA approval on 20 April 2004. |
| PubChem ID | 6005 |
| Additional PMIDs | NA |
| Additional sources of information | NA |
| Safety | NA |